Royalty Report: Drugs, Skin care, Wound Care – Collection: 314343

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Skin care
  • Wound Care
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 314343

License Grant
Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor) license, with the right to grant sublicenses, under the Licensed Patents to a compound (including any metabolites discovered by Deltanoid) selected from 2-methylene-19-nor-1a hydroxypregnalciferol, 2-methylene-19-nor-1a hydroxyhomopregnacalciforol or 2-methylene-19-nor-bis-homo-1a hydroxypregnacalciferol, to make, have made, use, sell, have sold, and import for topical treatments (topical treatments do not include patch delivery systems or mucous membrane delivery systems, such as a suppository, intended for systemic treatment) of skin diseases (including treatments of skin, hair and nails). Licensor agrees not to sell, market, or license any of the compounds that it currently owns or has right to use to any other company for the topical treatment of skin disease, including psoriasis, while this license is in effect.

Licensor specifically excludes from the foregoing license and reserves for itself the exclusive right to, and the right to license others to, make, have made, use, sell, have sold, or import any Cosmetic Product which contains 2-,methylene-19-nor-1a hydroxyhomopregnacalciferol. If the selected compound is 2-methylene-19-nor-1a-hydroxyhomopregnacalciferol, or 2-methylene-19-nor-bis-homo-1a hydroxypregnacalciferol, or 2-methylene-19-nor-1a hydroxypregnacalciferol, Licensor specifically excludes from the foregoing license and reserves for itself the exclusive right to, and the right to license others to, make, have made, use, sell, have sold, or import any treatment of cancer or renal osteodystrophy.

License Property
US patent #5,936,133 – 2-alkylidene-19-nor-vitamin D compounds
US patent #5,843,928 – 2-alkylidene-19-nor-vitamin D compounds
US patent #5,945,410 – 2-alkyl-19-nor-vitamin D compounds

Product Compound shall mean a Compound which is the active ingredient in a Product.

Cosmetic Product shall mean any product approved, made, used, sold and marketed for nonprescription cosmetic applications, which does not contain a Product Compound unless (a) such Product Compound is 2-methylene-19-nor-homopregnacalciferol, and (b) the concentration of 2-methylene-19-nor-homopregnacalciferol in the applicable  product is no greater than 5 parts per million.

Compound shall mean either 2-methylene-19-nor-1a hydroxypregnacalciferol, 2-methylene-19-nor-1a hydroxyhomopregnacalciferol, or 2-methylene-19-nor-bis-homo-1a hydroxypregnacalciferol as claimed in a Licensed Patent.

Field of Use
Becocalcidiol is a topical product candidate for the treatment of mild to moderate psoriasis, has completed a phase IIb clinical trial.

Psoriasis is a chronic disease of the skin characterized by red patches covered with white scales that can occur on any part of the body.

The field of use is for topical treatments (topical treatments do not include patch delivery systems or mucous membrane delivery systems, such as a suppository, intended for systemic treatment) of skin diseases (including treatments of skin, hair and nails).

Licensee is a pharmaceutical company focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas including chronic skin disease.

IPSCIO Record ID: 266761

License Grant
For the sublicense, Licensor grants an exclusive, even as to Licensor, license in the Territory, with the right to grant sublicenses, under the Licensor Inlicensed Patents and the Licensor Owned Patents to the extent necessary to make, have made, use, sell, have sold, and import the Compound.
License Property
Product shall mean any product which contains the Compound as one of its active ingredients, which product is being developed or is approved for topical treatments (topical treatments do not include patch delivery systems or mucous membrane delivery systems, such as a suppository.

Combination Product shall mean a Product containing the Compound and at least one other active pharmaceutical ingredient.

The Compound shall mean (20S)-2-methylene-19-nor-bis-homo-1a hydroxypregnacalciferol, also referred to as becocalcidiol.

Field of Use
The field of use is for topical treatments (topical treatments do not include patch delivery systems or mucous membrane delivery systems, such as a suppository, intended for systemic treatment) of skin diseases, including treatments of skin, hair and nails.

IPSCIO Record ID: 279377

License Grant
Licensor grants to Licensee and Affiliates of Licensee under the Licensed Patent Rights a non-exclusive license to make, have made, use, sell, and distribute in the Territory Licensed Products except through the Excluded Channel of Trade.
License Property
Licensed Products shall include any cosmetic and/or dermatologic preparation covered by the Licensed Patent Rights (a) containing glycolic acid and/or its salts (1) for the treatment of human skin wrinkles and/or fine lines on the human skin; (2) the treatment of dry skin; (3) as a skin cleanser; (4) as a hair conditioner; (5) as a shampoo; or (b) cosmetic and dermatologic preparations containing glycolic acid and/or its salts, in combination with salicylic acid for the treatment of acne; or (c) cosmetic and dermatologic preparations containing glycolic acid and/or its salts in combination with two percent (2%) or less of hydroquinone for the treatment of pigmented spots on human skin.

Licensed Patent Rights shall mean, those portions of the patents and patent applications, and all divisions, continuations, continuations-in-part, reissues, reexaminations and extensions thereof; (a) covering only cosmetic and dermatologic preparations containing glycolic acid and/or its salts for (1) the treatment of human skin wrinkles and/or fine lines on the human skin; (2) the treatment of dry skin; (3) as a skin cleanser; (4) as a hair conditioner; (5) as a shampoo; (b) covering only cosmetic and dermatologic preparations containing glycolic acid and/or its salts, in combination with salicylic acid for the treatment of acne; and (c) covering only cosmetic and dermatologic preparations containing glycolic acid and/or its salts in combination with two percent (2%) or less of hydroquinone for the treatment of pigmented spots on human skin.

Excluded Channel of Trade shall mean the mail order, multi-level and direct door-to-door markets. Notwithstanding the Excluded Channel of Trade herein, Licensee may process orders made by customers of Licensee as a result of 800 telephone, toll-free telephone or telephone orders, provided that Licensee and its Affiliates shall not employ television, including without limitation, television infomercials, to advertise any 800 telephone, toll-free telephone or any telephone numbers to take, process or receive sales orders.

Field of Use
Patent rights were for products containing glycolic acids and its salts for the treatment of wrinkles and fine lines, dry skin, in combination with salicylic acid for the treatment of acne and in combination with hydroquinone 2% or less for the treatment of skin pigmentation, and as a skin cleanser, hair conditioner and shampoo.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.